Metformin: Current knowledge

Journal of Research in Medical Sciences

Volumn 19, Issue 7, 2014, Pages 658-664

  Nasri, Hamid ^a   Rafieian Kopaei, Mahmoud ^b  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHREKORD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Diabetes; Diabetes mellitus; Diabetic nephropathy; Glucose; Metformin; New applications; Polycystic ovary syndrome; Renoprotection

Indexed keywords

ADENOSINE MONOPHOSPHATE KINASE; ALBUMIN; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; ENZYME; GLUCOSE; GLUCOSE TRANSPORTER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; METFORMIN; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BLOOD PRESSURE; CHILL; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIARRHEA; DIZZINESS; DROWSINESS; DYSPNEA; FATIGUE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; LACTATION; LACTIC ACIDOSIS; MYALGIA; NAUSEA; NEOPLASM; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OVARY POLYCYSTIC DISEASE; OXIDATIVE STRESS; PREGNANCY; PREGNANCY DIABETES MELLITUS; REVIEW; STOMACH PAIN; SYSTEMATIC REVIEW (TOPIC); VOMITING;

EID: 84911472056     PISSN: 17351995     EISSN: 17357136     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. Scheen AJ, Paquot N. Metformin revisited: A critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. Diabetes Metab 2013;39:179-90.
2. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: An update. Ann Intern Med 2002;137:25-33.
3. Hundal RS, Inzucchi SE. Metformin: New understandings, new uses. Drugs 2003;63:1879-94.
4. Scarpello JH, Howlett HC. Metformin therapy and clinical uses. Diab Vasc Dis Res 2008;5:157-67.
5. Rafieian-Kopaei M, Baradaran A. Combination of metformin with other antioxidants may increase its renoprotective efficacy. J Ren Inj Prev 2013;2:35-6.
6. Seo-Mayer PW, Thulin G, Zhang L, Alves DS, Ardito T, Kashgarian M, et al. Preactivation of AMPK by metformin may ameliorate the epithelial cell damage caused by renal ischemia. Am J Physiol Renal Physiol 2011;301:F1346-57.
7. Sung JY, Choi HC. Metformin-induced AMP-activated protein kinase activation regulates phenylephrine-mediated contraction of rat aorta. Biochem Biophys Res Commun 2012;421:599-604.
8. Rosen P, Wiernsperger NF. Metformin delays the manifestation of diabetes and vascular dysfunction in Goto-Kakizaki rats by reduction of mitochondrial oxidative stress. Diabetes Metab Res Rev 2006;22:323-30.
9. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854-65.
10. Nasri H. On the occasion of the world diabetes day2013; Diabetes education and prevention; a nephrology point of view. J Ren Inj Prev 2013;2:31-2.
11. Tertti K, Ekblad U, Vahlberg T, Rönnemaa T. Comparison of metformin and insulin in the treatment of gestational diabetes: A retrospective, case-control study. Rev Diabet Stud 2008;5:95-101.
12. Balani J, Hyer SL, Rodin DA, Shehata H. Pregnancy outcomes in women with gestational diabetes treated with metformin or insulin: A case-control study. Diabet Med 2009;26:798-802.
13. Cheung NW. The management of gestational diabetes. Vasc Health Risk Manag 2009;5:153-64.
14. Kidson W. Polycystic ovary syndrome: A new direction in treatment. Med J Aust 1998;169:537-40.
15. National Collaborating Centre for Women’s and Children’s Health. Fertility: Assessment and treatment for people with fertility problems. London: Royal College of Obstetricians and Gynaecologists 2004;97:58-9.
16. Balen A. Royal college of Obstetricians and Gynaecologists. Metformin therapy for the management of infertility in women with polycystic ovary syndrome. December 2008 [Last cited on 2009]. p. 12-3.
17. The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod 2008;23:462-77.
18. Palomba S, Pasquali R, Orio F Jr, Nestler JE. Clomiphene citrate, metformin or both as first-step approach in treating anovulatory infertility in patients with polycystic ovary syndrome (PCOS): A systematic review of head-to-head randomized controlled studies and meta-analysis. Clin Endocrinol (Oxf) 2009;70:311-21.
19. Al-Inany H, Johnson N. Drugs for an ovulatory infertility in polycystic ovary syndrome. BMJ 2006;332:1461-2.
20. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev 2009:CD003053.
21. Radosh L. Drug treatments for polycystic ovary syndrome. Am Fam Physician 2009;79:671-6.
22. Palomba S, Orio F, Falbo A, Russo T, Tolino A, Zullo F. Clomiphene citrate versus metformin as first-line approach for the treatment of anovulation in infertile patients with polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:3498-503.
23. Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009;137:482-8.
24. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304-5.
25. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: A cohort study among people with type 2 diabetes. Diabetes Care 2009;32:1620-5.
26. Chong CR, Chabner BA. Mysterious metformin. Oncologist 2009;14:1178-81.
27. Ben Sahra I, Le Marchand Brustel Y, Tanti JF, Bost F. Metformin in cancer therapy: A new perspective for an old antidiabetic drug? Mol Cancer Ther 2010;9:1092-9.
28. Esteghamati A, Eskandari D, Mirmiranpour H, Noshad S, Mousavizadeh M, Hedayati M, et al. Effects of metformin on markers of oxidative stress and antioxidant reserve in patients with newly diagnosed type 2 diabetes: A randomized clinical trial. Clin Nutr 2013;32:179-85.
29. Shirzad H, Shahrani M, Rafieian-Kopaei M. Comparison of morphine and tramadol effects on phagocytic activity of mice peritoneal phagocytes in vivo. Int Immunopharmacol 2009;9: 968-70.
30. Shirzad M, Kordyazdi R, Shahinfard N, Nikokar M. Does royal jelly affect tumor cells? J HerbMed Plarmacol 2013;2:45-8.
31. Shirzad H, Kiani M, Shirzad M. Impacts of tomato extract on the mice fibrosarcoma cells. J HerbMed Pharmacol 2013;2:13-6.
32. Shirzad H, Taji F, Rafieian-Kopaei M. Correlation between antioxidant activity of garlic extracts and WEHI-164 fibrosarcoma tumor growth in BALB/c mice. J Med Food 2011;14:969-74.
33. Rafieian-Kopaei M. Medicinal plants and the human needs. J Herb Med Plarmacol 2012;1:1-2.
34. Nasri H, Rafieian-Kopaei M. Metformin improves diabetic kidney disease. J Nephropharmacol 2012;1:1-2.
35. Nayer A, Ortega LM. Catastrophic antiphospholipid syndrome: A clinical review. J Nephropathol 2014;3:9-17.
36. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction and natural course of HIV-1 protease-inhibitor-associated li-podystrophy, hyperlipidemia, and diabetes mellitus: A cohort study. Lancet 1999;353:2093-9.
37. Shahbazian H. World diabetes day; 2013. J Ren Inj Prev 2013; 2: 123-4.
38. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000;275:20251-4.
39. Saint-Marc T, Touraine JL. Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy. AIDS 1999;13:1000-2.
40. Rafieian-Kopaei M, Nasri H. Ginger and diabetic nephropathy. J Ren Inj Prev 2012;2:9-10.
41. Baradaran A. Lipoprotein (a), type 2 diabetes and nephropathy; the mystery continues. J Nephropathol 2012;1:126-9.
42. Nasri H. Renoprotective effects of garlic. J Ren Inj Prev 2012;2:27-8.
43. Nasri H, Behradmanesh S, Maghsoudi AR, Ahmadi A, Nasri P, Rafieian-Kopaei M. Efficacy of supplementary vitamin D on improvement of glycemic parameters in patients with type 2 diabetes mellitus: A randomized double blind clinical trial. J Ren Inj Prev 2014;3:31-4.
44. Tavafi M. Complexity of diabetic nephropathy pathogenesis and design of investigations. J Ren Inj Prev 2013;2:61-5.
45. Behradmanesh S, Nasri P. Serum cholesterol and LDL-C in association with level of diastolic blood pressure in type 2 diabetic patients. J Ren Inj Prev 2012;1:23-6.
46. Rahimi Z. ACE insertion/deletion (I/D) polymorphism and diabetic nephropathy. J Nephropathol 2012;1:143-51.
47. Nasri H. Comment on: Serum cholesterol and LDL-C in association with level of diastolic blood pressure in type 2 diabetic patients. J Ren Inj Prev 2012;1:13-4.
48. Nasri H. Acute kidney injury and beyond. J Ren Inj Prev 2012;21:1-2.
49. Rouhi H, Ganji F. Effect of N-acetyl cysteine on serum Lipoprotein (a) and proteinuria in type 2 diabetic patients. J Nephropathol 2013;2:61-6.
50. Tavafi M. Diabetic nephropathy and antioxidants. J Nephropathol 2013;2:20-7.
51. Behradmanesh S, Derees F, Rafieian-kopaei M. Effect of Salvia officinalis on diabetic patients. J Ren Inj Prev 2013;2:57-9.
52. Kadkhodaee M, Sedaghat Z. Novel renoprotection methods by local and remote conditioning. J Ren Inj Prev 2014;3:37-8.
53. Tavafi M. Protection of renal tubules against gentamicin induced nephrotoxicity. J Ren Inj Prev 2012;2:5-6.
54. G heissari A. Acute kidney injury and renal angina. J Ren Inj Prev 2013;2:33-4.
55. Nasri H. Preventive role of erythropoietin against aminoglycoside renal toxicity induced nephropathy; Current knowledge and new concepts. J Ren Inj Prev 2012;2:29-30.
56. Nematbakhsh M, Ashrafi F, Pezeshki Z, Fatahi Z, Kianpoor F, Sanei MH, et al. A histopathological study of nephrotoxicity, hepatoxicity or testicular toxicity: Which one is the first observation as side effect of Cisplatin-induced toxicity in animal model. J Nephropathol 2012;1:190-3.
57. Cadenas E, Boveris A, Ragan CI, Stoppani AO. Production of superoxide radicals and hydrogen peroxide by NADH-ubiquinone reductase and ubiquinol-cytochrome c reductase from beef-heart mitochondria. Arch Biochem Biophys 1977;180:248-57.
58. Rafieian-Kopaie M, Baradaran A. Plants antioxidants: From laboratory to clinic. J Nephropathol 2013;2:152-3.
59. B aradaran A, Mahmoud Rafieian-Kopaei M. Histopathological study of the combination of metformin and garlic juice for the attenuation of gentamicin renal toxicity in rats. J Ren Inj Prev 2012;2:15-21.
60. Hernandez GT, Nasri H. World Kidney Day 2014: Increasing awareness of chronic kidney disease and aging. J Ren Inj Prev 2014;3:3-4.
61. Amini FG, Rafieian-Kopaei M, Nematbakhsh M, Baradaran A, Nasri H. Ameliorative effects of metformin on renal histologic and biochemical alterations of gentamicin-induced renal toxicity in Wistar rats. J Res Med Sci 2012;17:621-5.
62. Rafieian-Kopaei M, Baradaran A. Teucrium polium and kidney. J Ren Inj Prev 2012;2:3-4.
63. Tolouian R, Hernandez G. Prediction of diabetic nephropathy: The need for a sweet biomarker. J Nephropathol 2013;2:4-5.
64. Piwkowska A, Rogacka D, Jankowski M, Dominiczak MH, Stepinski JK, Angielski S. Metformin induces suppression of NAD(P) H oxidase activity in podocytes. Biochem Biophys Res Commun 2010;393:268-73.
65. Merriwether DA, Clark AG, Ballinger SW, Schurr TG, Soodyall H, Jenkins T, et al. The structure of human mitochondrial DNA variation. J Mol Evol 1991;33:543-55.
66. Suzuki S, Hinokio Y, Komatu K, Ohtomo M, Onoda M, Hirai S, et al. Oxidative damage to mitochondrial DNA and its relationship to diabetic complications. Diabetes Res Clin Pract 1999;45:161-8.
67. K im J, Shon E, Kim CS, Kim JS. Renal podocyte injury in a rat model of type 2 diabetes is prevented by metformin. Exp Diabetes Res 2012;2012:210821.
68. Liu Z, Li J, Zeng Z, Liu M, Wang M. The antidiabetic effects of cysteinyl metformin, a newly synthesized agent, in alloxan-and streptozocin-induced diabetic rats. Chem Biol Interact 2008;173: 68-75.
69. Gheshlaghi F. Toxic renal injury at a glance. J Ren Inj Prev 2012;1:15-6.
70. Gheissari A, Hemmatzadeh S, Merrikhi A, Fadaei Tehrani S, Madihi Y. Chronic kidney disease in children: A report from a tertiary care center over 11 years. J Nephropathol 2012;1:177-82.
71. Behradmanesh S, Nasri H. Association of serum calcium with level of blood pressure in type 2 diabetic patients. J Nephropathol 2013;2:254-7.
72. Kari J. Epidemiology of chronic kidney disease in children. J Nephropathol 2012;1:162-3.
73. Lalau JD. Lactic acidosis induced by metformin: Incidence, management and prevention. Drug Saf 2010;33:727-40.
74. Scheen AJ. Metformin and lactic acidosis. Acta Clin Belg 2011;66:329-31.
75. Howlett HC, Bailey CJ. A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Saf 1999;20:489-503.
76. Emslie-Smith AM, Boyle DI, Evans JM, Sullivan F, Morris AD. DARTS/MEMO Collaboration. Con-traindications to metformin therapy in patients with Type 2 diabetes-a population-based study of adherence to prescribing guidelines. Diabet Med 2001;18:483-8.
77. Sulkin TV, Bosman D, Krentz AJ. Contraindications to metformin therapy in patients with NIDDM. Diabetes Care 1997;20:925-8.
78. Holstein A, Nahrwold D, Hinze S, Egberts EH. Contraindications to metformin therapy are largely disregarded. Diabet Med 1999;16:692-6.
79. Salpeter SR, Greyber E, Pasternak GA, Salpeter Posthumous EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mel-litus. Cochrane Database Syst Rev 2010.
80. Mardani S, Nasri H, Hajian S, Ahmadi A, Kazemi R, Rafieian-Kopaei M. Impact of Momordica charantia extract on kidney function and structure in mice. J Nephropathol 2014;3:35-40.
81. Roussel R, Travert F, Pasquet B, Wilson PW, Smith SC Jr, Goto S, et al. Reduction of Atherothrombosis for Continued Health (REACH) Registry Investigators. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 2010;170:1892-9.
82. Isoherranen M, Thummel KE. Drug metabolism and transport during pregnancy: How does drug disposition change during pregnancy and what are the mechanisms that cause such changes? Drug Metab Dispos 2013;41:256-62.
83. Eyal S, Easterling TR, Carr D, Umans JG, Miodovnik M, Hankins GD, et al. Pharmacokinetics of metformin during pregnancy. Drug Metab Dispos 2010;38:833-40.
84. Lautatzis ME, Goulis DG, Vrontakis M. Efficacy and safety of metformin during pregnancy in women with gestational diabetes mellitus or polycystic ovary syndrome: A systematic review. Metab Clin Exp 2013;62:1522-34.
85. Ardalan MR, Rafieian-Kopaie M. Antioxidant supplementation in hypertension. J Ren Inj Prev 2014;3:39-40.
86. The Endocrine Society. Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2013:2013-350.
87. Tamadon MR, Baradaran A, Rafieian-Kopaei M. Antioxidant and kidney protection; differential impacts of single and whole natural antioxidants. J Ren Inj Prev 2014;3:41-2.
88. Nasri H, Behradmanesh S, Ahmadi A, Rafieian-Kopaei M. Impact of oral vitamin D (cholecalciferol) replacement therapy on blood pressure in type 2 diabetes patients: A randomized, double-blind, placebo controlled clinical trial. J Nephropathol 2014;3:29-33.
89. Pickering JW, Endre ZH. The definition and detection of acute kidney injury. J Ren Inj Prev 2014;3:21-5.
90. Blumer I, Hadar E, Hadden DR, Jovanovič L, Mestman JH, Murad MH, et al. Diabetes and pregnancy: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2013;98:4227-49.